Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

1.

Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, Klatzmann D.

Front Immunol. 2015 Apr 15;6:171. doi: 10.3389/fimmu.2015.00171. eCollection 2015.

2.

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.

Klatzmann D, Abbas AK.

Nat Rev Immunol. 2015 May;15(5):283-94. doi: 10.1038/nri3823. Epub 2015 Apr 17.

PMID:
25882245
3.

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Mar;25(3):399-400. doi: 10.1038/cr.2015.28. No abstract available.

PMID:
25732764
4.

TCR sequences and tissue distribution discriminate the subsets of naïve and activated/memory Treg cells in mice.

Bergot AS, Chaara W, Ruggiero E, Mariotti-Ferrandiz E, Dulauroy S, Schmidt M, von Kalle C, Six A, Klatzmann D.

Eur J Immunol. 2015 May;45(5):1524-34. doi: 10.1002/eji.201445269. Epub 2015 Apr 7.

PMID:
25726757
5.

C-terminal cleavage of human Foxp3 at a proprotein convertase motif abrogates its suppressive function.

Elhage R, Cheraï M, Levacher B, Darrasse-Jeze G, Baillou C, Zhao X, Khatib AM, Piaggio E, Klatzmann D.

Scand J Immunol. 2015 Apr;81(4):229-39. doi: 10.1111/sji.12275.

PMID:
25683871
6.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

PMID:
25634360
7.

Th1 and th17 cytokines drive inflammation in takayasu arteritis.

Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P.

Arthritis Rheumatol. 2015 May;67(5):1353-60. doi: 10.1002/art.39037.

PMID:
25604824
8.

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L.

Cell Res. 2015 Feb;25(2):208-24. doi: 10.1038/cr.2015.3. Epub 2015 Jan 13. Erratum in: Cell Res. 2015 Mar;25(3):399-400. Zörnig, Inka [added]; Hassel, Jessica [added].

PMID:
25582080
9.

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes.

Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR.

Diabetes. 2015 Jun;64(6):2172-83. doi: 10.2337/db14-1322. Epub 2015 Jan 9.

PMID:
25576057
10.

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.

Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D.

Curr Diab Rep. 2014 Dec;14(12):553. doi: 10.1007/s11892-014-0553-6.

PMID:
25344788
11.

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA.

Blood. 2014 Dec 4;124(24):3572-6. doi: 10.1182/blood-2014-07-587493. Epub 2014 Oct 16.

12.

Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions.

Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D.

Front Immunol. 2014 Aug 21;5:389. doi: 10.3389/fimmu.2014.00389. eCollection 2014. Review.

13.

A novel strategy for molecular signature discovery based on independent component analysis.

Pham HP, Dérian N, Chaara W, Bellier B, Klatzmann D, Six A.

Int J Data Min Bioinform. 2014;9(3):277-304.

PMID:
25163169
14.

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, Cabanne L, Churlaud G, Suarez F, Socié G, Gregoire L, Debbache K, Bernard C, Beaumont JL, Azar N, Boyer O, Roudot-Thoraval F, Cohen JL, Cordonnier C, Lemoine FM, Klatzmann D.

Leukemia. 2014 Dec;28(12):2406-10. doi: 10.1038/leu.2014.237. Epub 2014 Aug 8. No abstract available.

PMID:
25102947
15.

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.

Vlková V, Štěpánek I, Hrušková V, Šenigl F, Mayerová V, Šrámek M, Šímová J, Bieblová J, Indrová M, Hejhal T, Dérian N, Klatzmann D, Six A, Reiniš M.

Oncotarget. 2014 Aug 30;5(16):6923-35.

16.

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.

PMID:
24622415
17.

Th1 response and systemic treg deficiency in inclusion body myositis.

Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, Wanschitz J, Musset L, Charuel JL, Eymard B, Salomon B, Duyckaerts C, Maisonobe T, Dubourg O, Herson S, Klatzmann D, Benveniste O.

PLoS One. 2014 Mar 4;9(3):e88788. doi: 10.1371/journal.pone.0088788. eCollection 2014.

18.

Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer.

Churlaud G, Jimenez V, Ruberte J, Amadoudji Zin M, Fourcade G, Gottrand G, Casana E, Lambrecht B, Bellier B, Piaggio E, Bosch F, Klatzmann D.

Clin Immunol. 2014 Apr;151(2):114-26. doi: 10.1016/j.clim.2014.02.003. Epub 2014 Feb 19.

PMID:
24576619
19.

CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.

Terrier B, Nagata S, Ise T, Rosenzwajg M, Pastan I, Klatzmann D, Saadoun D, Cacoub P.

Arthritis Rheumatol. 2014 Feb;66(2):433-43. doi: 10.1002/art.38222.

PMID:
24504816
20.

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Kirchmeier M, Fluckiger AC, Soare C, Bozic J, Ontsouka B, Ahmed T, Diress A, Pereira L, Schödel F, Plotkin S, Dalba C, Klatzmann D, Anderson DE.

Clin Vaccine Immunol. 2014 Feb;21(2):174-80. doi: 10.1128/CVI.00662-13. Epub 2013 Dec 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk